AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03507205 — intervention group
Intervention type: DEVICE
Intervention: Xience V/Promus; Cypher
Description: Durable polymer-coated everolimus-eluting stents; Sirolimus-eluting stents
Study NCT03507205 — intervention group
Intervention type: DEVICE
Intervention: DP-ZES-RI
Description: Durable polymer-coated zotarolimus-eluting stents
Study NCT02675660 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules once daily
Study NCT03023358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chidamide
Description: 30mg po twice a week
Study NCT03023358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 750mg/m2 iv on day 1
Study NCT01254643 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V503
Description: V503 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
Study NCT03023072 — intervention group
Intervention type: OTHER
Intervention: Incontinence Detection System
Study NCT03507205 — intervention group
Intervention type: DEVICE
Intervention: Endeavor; Resolute
Description: Durable polymer-coated zotarolimus-eluting stents
Study NCT01576497 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNA
Description: EUS-FNA with suction/10, 15, 20 to-and-fro motion vs. EUS-FNA without suction/10, 15, 20 to-and-fro motion Visual assessment as stoping rule: 20 to-and-fro motion at different site will be performed when EUS-FNA sampling with 10, 15, 20 to-and-fro motion is unsatisfactory.
Study NCT01576497 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNA with suction
Description: For this prospective single-blinded randomized trial, two 10cc syringes was prepared. Two syringe was provided as same performance. However, one syringe is falsely made as suction syringe (fake one). During EUS-FNA, two syringe is randomly assigned and loaded by a nurse. Thus, operator was blinded which syringe is with suction or without suction.
Study NCT01576497 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNA without suction
Description: For this prospective single-blinded randomized trial, two 10cc syringes was prepared. Two syringe was provided as same performance. However, one syringe is falsely made as suction syringe (fake one). During EUS-FNA, two syringe is randomly assigned and loaded by a nurse. Thus, operator was blinded which syringe is with suction or without suction.
Study NCT04339829 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dacomitinib
Description: Dacomitinib orally on a continuous daily basis at a starting dose of 45 mg QD
Study NCT00721240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast
Description: 5mg montelukast once daily for 12 weeks
Study NCT03023358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 750mg/m2 iv on day 1
Study NCT03023358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liposomal doxorubicin
Description: 30mg/m2 iv on day 1
Study NCT01991236 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: Educational video discussing risks and benefits of chronic use of systemic corticosteroids.
Study NCT03023358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin
Description: 30mg/m2 iv on day 1
Study NCT03023358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine
Description: 1.4mg/m2 iv on day 1
Study NCT03023358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: 1.4mg/m2 iv on day 1
Study NCT03023358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: 100mg/d po on day 1-5
Study NCT03023358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100mg/d po on day 1-5
Study NCT01411761 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Reflor
Description: 5 million unit/day, first 15 day of life
Study NCT01411761 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: serum physiologic
Description: 1 cc added to one feeding in a day
Study NCT00516698 — intervention group
Intervention type: GENETIC
Intervention: polymorphism analysis
Study NCT01991236 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Script
Description: Standard scripted discussion of risks and benefits of chronic corticosteroid usage read to patients.
Study NCT04515758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and Cognitive Training
Description: Exercise: 12-week, twice-weekly 60-minute program. Each session includes a brief 5 minute educational lesson on a health-related topic (i.e. healthy eating, good posture, etc.). Each participant receives individualized and progressive exercise program from qualified exercise providers (YMCA instructors). The programs include whole body exercises including squats, rows, chest press, bicep/tricep exercises, shoulder exercises, and core exercises. A 5 warm-up is done (individually or in a group) and a 5 minute group cool-down (stretching) is done each class. Cognitive training: focuses on dual-task training (provided by an Android tablet). Each cognitive task requires the participant to choose and execute the response appropriate for the stimuli presented. Participants must prioritize their response and perform tasks as fast as possible while maintaining accuracy. The difficulty of the training is individualized and progressive based on their ongoing performance.
Study NCT04515758 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Training Only
Description: Exercise: 12-week, twice-weekly 60-minute program. Each session includes a brief 5 minute educational lesson on a health-related topic (i.e. healthy eating, good posture, etc.). Each participant receives individualized and progressive exercise program from qualified exercise providers (YMCA instructors). The programs include whole body exercises including squats, rows, chest press, bicep/tricep exercises, shoulder exercises, and core exercises. A 5 warm-up is done (individually or in a group) and a 5 minute group cool-down (stretching) is done each class.
Study NCT00516698 — intervention group
Intervention type: OTHER
Intervention: high performance liquid chromatography
Study NCT04649515 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TY027
Description: TY027 Injection, (100 mg/5 mL/Vial), SARS-CoV-2 Monoclonal Antibody (mAb) - 1,500 mg of TY027
Study NCT04649515 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TY027
Description: TY027 Injection, (100 mg/5 mL/Vial), SARS-CoV-2 Monoclonal Antibody (mAb) - 2,000 mg of TY027
Study NCT04649515 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: Placebo
Study NCT01219985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard and respiratory-gated PET acquisitions
Description: After fasting for at least 6 hours, normal glucose blood level was checked and each patient received an intravenous injection of 18F-FDG (5MBq/kg). After a 60-minute uptake phase in a quiet environment, patients underwent the PET/CT examination.~* Whole-body PET/CT (Ungated session) The Ungated acquisition consisted in a whole-body, free-breathing CT followed by standard multistep PET, used as routine clinical practice in the department.~* Respiratory-gated PET/CT (CT-based session) The CT-based method consisted in an additional single-step, 10-minute List Mode respiratory gated PET acquisition followed by an end-expiration breath-hold CT added to the end of the clinical protocol, with continuous respiratory signal recording during these examinations.
Study NCT03186729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithrombotic Agent
Description: Anticoagulant or antiplatelet drugs
Study NCT00516698 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study NCT00516698 — intervention group
Intervention type: PROCEDURE
Intervention: radiomammography
Study NCT03661281 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Jebsen Taylor Hand function test
Description: consists of seven test items, which are felt to represent various hand activities. These test items include: writing a short sentence; turning over 365 inch cards; picking up small objects and placing in a container; stacking checkers; simulated eating; moving empty large cans; and moving weighted large cans.
Study NCT04488926 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) microgranules
Description: Micronized and ultra-micronized Palmitoylethanolamide is on the market in Italy as a Food for Special Medical Purposes
Study NCT04488926 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo microgranules 1800mg
Description: Placebo was prepared to be indistinguishable from color and flavor from the Product
Study NCT03661281 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pinch strength
Description: Measured in every splint position using a standard dynamometer
Study NCT03661281 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Grooved pegboard test
Description: Time will be measured and compared between control, MP splint and IP splint
Study NCT04488926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: (antidepressants, anticonvulsants, muscle relaxants, weak opiates, etc..) consolidated for at least 3 months
Study NCT04488926 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard Therapy
Description: (antidepressants, anticonvulsants, muscle relaxants, weak opiates, etc..) consolidated for at least 3 months
Study NCT04488926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rescue Drug
Description: Use as needed allowed
Study NCT04488926 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rescue Drug
Description: Use as needed allowed
Study NCT04406649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine
Description: Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
Study NCT05528393 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: blood sampling
Study NCT04254848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral stereognostic test
Description: Six test pieces were selected from the 20 shapes of test pieces from National Institute of Dental Research. The test pieces comprises of 6 shaped forms which include circle, plus, square, rectangular, triangle and toroid shaped. A 2mm stainless steel wire was bent forming the test piece shape following the standard dimensions (13mm length and 2mm thickness)as described by National Institute of Dental Research to serve as the test pieces mould. Using the six test piece moulds, light cured acrylic resin test samples were fabricated. The test samples were trimmed and polished to meet the standardized measurements. A total of 240 test sample (6 samples for each patient) for 20 completely edentulous patients with maxillary tori and 20 completely edentulous patients without tori were made for the study. The test pieces were attached to dental floss to prevent any accidentally aspiration during the study.
Study NCT01807598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Study NCT04514822 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Dynamic PET
Description: After transmission CT scan for subsequent PET data attenuation correction, continual dynamic clinical PET scans were performed in a single bed position immediately after 18F-FDG intravenously injection (210 ± 30 MBq) in list mode for 60 minutes in supine position, dynamic 48 time frames PET/CT imaging was obtained.And then underwent whole body static PET scan.
Study NCT03977103 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose irradiation conditioning + Treg/Tcon
Description: High dose irradiation based conditioning regimens followed by infusion of donor regulatory and conventional T cells and purified CD34+ hematopoietic stem cell transplantation
Study NCT01849406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nasal spray Budesonide
Description: one week therapy of nasal budesonide twice per day
Study NCT01849406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nasal spray Normal Saline
Description: one week therapy of nasal normal saline twice per day
Study NCT02717494 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PPV-23
Description: PPV-23 was a polysaccharide PNC vaccine, licensed in Brazil, directed against 23 serotypes.
Study NCT02717494 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV-10
Description: PCV-10 was a conjugate PNC vaccine, licensed in Brazil, directed against 10 serotypes.
Study NCT02717494 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: NaCl was the placebo for the study against which the two vaccines were compared during pregnancy.
Study NCT01887184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine 1.5mcg/kg was given intranasally
Study NCT01887184 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intranasal saline was given
Study NCT03960112 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mpMRI
Description: mpMRI in the detection of prostate cancer in a per patient analysis using cystoprostatectomy specimen
Study NCT01940835 — intervention group
Intervention type: PROCEDURE
Intervention: Upper endoscopy with small bowel biopsies and brushings.
Study NCT01940835 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Description: Blood will be collected for serum, DNA, and peripheral blood mononuclear cells (PBMC).
Study NCT01940835 — intervention group
Intervention type: OTHER
Intervention: Stool sample
Description: Stool samples will be collected at baseline for future microbiome and virome studies.
Study NCT00292019 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic
Description: Patients with prostate cancer who are eligible for a radical prostatectomy will have their surgery conducted with the aid of surgical robots.
Study NCT00731679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Study NCT00731679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01374633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1: Sevoflurane
Description: Mean sevoflurane infusion rate will be around 6 ml/h or 72 ml for 12 hours. Maximal infusion rate will be around 12 ml/h, or 144 ml for 12 hours. Packaging: bottle containing 250 ml of liquid sevoflurane for evaporation. Administration mode: anaesthetic conserving device for volatile anaesthetics.
Study NCT04479774 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compelled Body Weight Shift Technique
Description: Routine Physical Therapy with 0.6 cm thickness insole inserted in shoe of unaffected side and following exercises were performed by patients~* Muscle re-education~* Sit to stand exercise , 4 to 10 repetitions~* Supported heel raise to 10 repetitions with 3 sets~* Supported squat exercise tibialis anterior and quads muscles to 10 repetitions with 3 sets~* Gait training~* Forward walk in parallel bars with number of 10 rounds.~* Task oriented training balance training~* A. Stepping exercise on 15 cm height step and number of repetitions 10.~* B. Tandem standing for 10 seconds.~* C. Reaching exercise in which patient performed reaching for object in therapists hand and the number of repetitions was 10.
Study NCT04479774 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Compelled Body Weight Shift Technique without insole
Description: Routine Physical Therapy without 0.6 cm thickness insole inserted in shoe of unaffected side and following exercises were performed by patients~* Muscle re-education~* Sit to stand exercise , 4 to 10 repetitions~* Supported heel raise to 10 repetitions with 3 sets~* Supported squat exercise tibialis anterior and quads muscles to 10 repetitions with 3 sets~* Gait training~* Forward walk in parallel bars with number of 10 rounds.~* Task oriented training balance training~* A. Stepping exercise on 15 cm height step and number of repetitions 10.~* B. Tandem standing for 10 seconds.~* C. Reaching exercise in which patient performed reaching for object in therapists hand and the number of repetitions was 10.
Study NCT01633164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCI Reinvention Protocol Participants
Description: The intervention involves participation in a six week psychologically-based educational intervention. During the course, 8 specific skills are reviewed in order to specifically address reframing a person's method of looking at events, build confidence by focusing on personal strengths, develop methods of recognizing and appreciating the good in one's life and express gratitude for positive attributes. These skills are presented in a specific sequence so that participants can gain mastery of introductory concepts before undertaking those that are both more difficult and complex.
Study NCT01633164 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist Group
Description: Wait list arm will begin study intervention after 4 1/2 months.
Study NCT02964000 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low level 1 Watt
Description: The Phoenix Thera-Lase System will be on 1 watt
Study NCT02964000 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phoenix Thera-Lase System 42
Description: The Phoenix Thera-Lase System will be on 42 watts
Study NCT02964000 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phoenix Thera-Lase System 74
Description: The Phoenix Thera-Lase System will be on 74 watts
Study NCT02134925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02134925 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02134925 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MUC1 Peptide-Poly-ICLC Vaccine
Description: Given SC
Study NCT02635906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 hours
Description: BED REST FOR TWO HOURS AFTER CORONARY ARTERIOGRAPHY OR CORONARY ANGIOPLASTY
Study NCT02635906 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 4 hours
Description: BED REST FOR FOUR HOURS AFTER CORONARY ARTERIOGRAPHY OR CORONARY ANGIOPLASTY
Study NCT02134925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02134925 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02134925 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Given SC
Study NCT01550809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iBolus
Description: Insulin bolus calculated from data obtained through CGM
Study NCT01550809 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tBolus (traditional bolus)
Description: Insulin bolus dose calculated using the standard procedure based on the insulin-to-carbohydrate ratio
Study NCT00847002 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Wound Care
Study NCT00847002 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexitouch System with Standard Wound Care
Study NCT02352844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study NCT03313700 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic Distal Gastrectomy
Description: After exclusion of T4b, bulky lymph nodes, or distant metastasis case, robotic distal gastrectomy will be performed in the experimental group.
Study NCT03313700 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Distal Gastrectomy
Description: After exclusion of T4b, bulky lymph nodes, or distant metastasis case, laparoscopic distal gastrectomy will be performed in the comparator group.
Study NCT01377662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OND-PR002 and MPh-IR
Description: Drug: OND-PR002~Single daily oral doses of 8 mg Ond-PR002~Drug: MPh-IR~Single daily oral doses of 20 mg MPh-IR
Study NCT01377662 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Two dextrose capsules for Ond-PR002 and MPh-IR
Description: Single daily oral doses
Study NCT00590863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSRI + placebo
Description: Participants will take escitalopram (10 - 20 mg/day)+ placebo (1 to 3 pills per day). Medications taken orally. Participants will take escitalopram plus placebo for up to 28 weeks. Dosages were adjusted as need at each clinic visit.
Study NCT00590863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram + Bupropion SR
Description: Participant will take Burpopion SR (150 to 450 mg/day) + Escitalopram (10 to 20 mg/day) for up to 28 weeks. Medications taken orally. Bupropion SR was blinded, and escitalopram was given open label. Dosages were adjusted as need at each clinic visit.
Study NCT00590863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine XR + Mirtazapine
Description: Participants will take Venlafaxine XR (75 to 225 mg/day) + Mirtazapine (15 to 45 mg/day) for up to 28 weeks. Medications taken orally. Venlafaxine XR was blinded, and mirtazapine was given open label. Dosages were adjusted as need at each clinic visit.
Study NCT04603118 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Optic ultrasonography